Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH